Seeking Alpha

Credit Suisse warns that a sale of Dendreon (DNDN -0.7%) is not likely in the near-term, and...

Credit Suisse warns that a sale of Dendreon (DNDN -0.7%) is not likely in the near-term, and said it doesn't appear that any major players are interested in acquiring the company. The firm adds that Dendreon has been quietly reorganizing its business development team and believes its head, David Ghesquiere, left the company over a week ago.
From other sites
Comments (2)
  • ed naples
    , contributor
    Comments (5) | Send Message
     
    does he believe or know for sure if David Ghesquiere has left the company and for what reason?
    26 Jun 2012, 04:48 PM Reply Like
  • Walkingwounded
    , contributor
    Comments (250) | Send Message
     
    Wow, it is not likely, yet possible. May or may not happen. What actionable advice. Did Davie leave? Did he do a good job? Perhaps he deserved to be let go. Does it make sense that BP would not be interested in new ways to treat cancer? I would love to know Credit Swiss' trading position in the company. Just BS.
    26 Jun 2012, 06:15 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs